MEDICINE SUMMARY. Atomoxetine Hydrochloride Layer 1 of 8 ALL REPORT DATES. Tachycardia. Supraventricular tachycardia. Palpitations.

Size: px
Start display at page:

Download "MEDICINE SUMMARY. Atomoxetine Hydrochloride Layer 1 of 8 ALL REPORT DATES. Tachycardia. Supraventricular tachycardia. Palpitations."

Transcription

1 Atomoxetine Hydrochloride Layer 1 of 8 ALL REPORT DATES Causality Unclear Exclud Total Sole Suspected - Cases Including Medicine - Occurrences of Medicine - Reactions Related to Medicine Blood and lymphatic system disorders Cardiac disorders Eye disorders Gastrointestinal disorders General disorders and administration site conditions Hepatobiliary disorders Infections and infestations Injury, poisoning and procedural complications Investigations Coagulopathy Tachycardia Supraventricular tachycardia Palpitations Eyelid ptosis Strabismus Visual disturbance Pancreatitis Gastrointestinal disorder Diarrhoea Dyspepsia Abdominal pain Abdominal pain upper Faecal incontinence Nausea Vomiting Feeling cold Feeling hot Condition aggravated Irritability Chest pain Pain Drug interaction Drug ineffective Hepatitis Orchitis Fall Heart rate increased Page 1

2 Atomoxetine Hydrochloride Layer 1 of 8 Investigations Blood pressure increased Metabolism and nutrition disorders Musculoskeletal and connective tissue disorders Nervous system disorders Psychiatric disorders Visual acuity tests abnormal Weight decreased Anorexia Arthralgia Joint swelling Muscle rigidity Growth retardation Facial spasm Headache Intracranial pressure increased Disturbance in attention Psychomotor hyperactivity Syncope Motor dysfunction Dizziness Paraesthesia Hypoaesthesia Convulsion Obsessive-compulsive disorder Agitation Anxiety Nervousness Panic attack Restlessness Tic Paramnesia Depression Major depression Depressed mood Tearfulness Hallucination, auditory Thinking abnormal Affect lability Anger Page 2

3 Atomoxetine Hydrochloride Layer 1 of 8 Psychiatric disorders Emotional disorder Renal and urinary disorders Reproductive system and breast disorders Respiratory, thoracic and mediastinal disorders Skin and subcutaneous tissue disorders Social circumstances Surgical and medical procedures Vascular disorders Mood altered Mood swings Aggression Attention-seeking behaviour Homicidal ideation Hostility Social avoidant behaviour Abnormal behaviour Regressive behaviour Mental disorder Psychotic disorder Insomnia Sleep disorder Intentional self-injury Self injurious behaviour Self-injurious ideation Suicidal ideation Suicide attempt Urinary incontinence Balanitis Cough Throat tightness Periorbital oedema Rash Educational problem Therapy regimen changed Pallor Hypertension Page 3

4 DEXAMPHETAMINE SULPHATE Layer 2 of 8 ALL REPORT DATES Causality Unclear Exclud Total Sole Suspected - Cases Including Medicine - Occurrences of Medicine - Reactions Related to Medicine Blood and lymphatic system disorders Cardiac disorders Congenital, familial and genetic disorders Ear and labyrinth disorders Eye disorders Gastrointestinal disorders General disorders and administration site conditions Investigations Metabolism and nutrition disorders Neutropenia Tachycardia Palpitations Cardiomyopathy Multiple congenital abnormalitie Hearing impaired Tinnitus Mydriasis Photophobia Retinal pigmentation Vision blurred Abdominal pain Vomiting Cheilitis Stomatitis Dry mouth Chills Asthenia Fatigue Abasia Irritability Face oedema Drug effect decreased Drug ineffective Therapeutic response decrease Electroencephalogram abnorma Weight decreased Anorexia Page 4

5 DEXAMPHETAMINE SULPHATE Layer 2 of 8 Metabolism and nutrition disorders Hyponatraemia Musculoskeletal and connective tissue disorders Nervous system disorders Pregnancy, puerperium and perinatal conditions Psychiatric disorders Hypoglycaemia Myalgia Muscle spasms Muscle twitching Subarachnoid haemorrhage Headache Disturbance in attention Judgement impaired Dyskinesia Hyperkinesia Dystonia Tremor Hyperreflexia Hyporeflexia Dizziness Burning sensation mucosal Paraesthesia Neuralgia Dysarthria Speech disorder Hypertonia Hypotonia Serotonin syndrome Muscle contractions involuntary Convulsion Neonatal disorder Neurosis Obsessive-compulsive disorder Agitation Anxiety Nervousness Restlessness Confusional state Disorientation Page 5

6 DEXAMPHETAMINE SULPHATE Layer 2 of 8 Psychiatric disorders Depression Renal and urinary disorders Reproductive system and breast disorders Respiratory, thoracic and mediastinal disorders Skin and subcutaneous tissue disorders Depressed mood Delusion Hallucination Hallucination, auditory Hallucination, visual Thinking abnormal Anger Crying Mood swings Apathy Aggression Homicidal ideation Paranoia Abnormal behaviour Neglect of personal appearance Psychotic disorder Insomnia Suicidal ideation Renal pain Testicular disorder Bronchospasm Dyspnoea Hyperventilation Periorbital oedema Urticaria Erythema Rash erythematous Pruritus Rash Skin ulcer Alopecia Hyperhidrosis Nail discolouration Purpura Page 6

7 DEXAMPHETAMINE SULPHATE Layer 2 of 8 Surgical and medical procedures Therapy regimen changed Vascular disorders Peripheral ischaemia Orthostatic hypotension Page 7

8 METHYLPHENIDATE HYDROCHLORIDE Layer 3 of 8 ALL REPORT DATES Causality Unclear Excluded Total Death Outcome Sole Suspected - Cases Including Medicine - Occurrences of Medicine - Reactions Related to Medicine Blood and lymphatic system disorders Cardiac disorders Congenital, familial and genetic disorders Endocrine disorders Eye disorders Gastrointestinal disorders Anaemia Aplastic anaemia Pancytopenia Arrhythmia Tachycardia Cardiac arrest Ventricular fibrillation Palpitations Myocardial infarction Cardiomyopathy Tourette's disorder Hypothyroidism Eye oedema Eye pain Conjunctivitis Oculogyric crisis Photophobia Optic atrophy Retinal pigmentation Vision blurred Visual disturbance Tooth discolouration Gingival hyperplasia Pancreatitis Gastrointestinal inflammation Diarrhoea Abdominal pain Abdominal pain upper Page 8

9 METHYLPHENIDATE HYDROCHLORIDE Layer 3 of 8 Gastrointestinal disorders Abdominal discomfort 1 General disorders and administration site conditions Infections and infestations Injury, poisoning and procedural complications Investigations Nausea Vomiting Duodenal scarring Lip swelling Mouth ulceration Dry mouth Pyrexia Sudden death Fatigue Malaise Abasia Chest discomfort Condition aggravated Feeling abnormal Influenza like illness Irritability Swelling Face oedema Oedema peripheral Chest pain Pain Drug interaction Drug effect decreased Drug ineffective Drug withdrawal syndrome Mass Otitis media Infection Pharyngitis Rhinitis Viral infection Fall Wrong drug administered Electrocardiogram abnormal Page 9

10 METHYLPHENIDATE HYDROCHLORIDE Layer 3 of 8 Investigations Heart rate increased Metabolism and nutrition disorders Musculoskeletal and connective tissue disorders Neoplasms benign, malignant and unspecified (incl cysts and polyps) Nervous system disorders Heart rate irregular Blood pressure increased Androgens increased Bleeding time prolonged Prothrombin level decreased Corneal reflex decreased Intraocular pressure increased Weight decreased Weight increased Anorexia Decreased appetite Increased appetite Obesity Polydipsia Pain in jaw Myalgia Muscle twitching Muscle rigidity Growth retardation Sensation of heaviness Pseudolymphoma Neoplasm malignant Optic neuritis Headache Migraine Dementia Amnesia Choreoathetosis Dyskinesia Extrapyramidal disorder Hyperkinesia Psychomotor hyperactivity Tardive dyskinesia Dystonia Page 10

11 METHYLPHENIDATE HYDROCHLORIDE Layer 3 of 8 Nervous system disorders Tremor Psychiatric disorders Ataxia Coma Lethargy Somnolence Dizziness Formication Hyperaesthesia Paraesthesia Dysgeusia Dysarthria Visual field defect Hypertonia Neuroleptic malignant syndrom Poor quality sleep Neurosis Obsessive-compulsive disorder Agitation Anxiety Nervousness Obsessive thoughts Fear Panic attack Restlessness Head banging Tic Distractibility Logorrhoea Lack of spontaneous speech Confusional state Disorientation Depression Tearfulness Hallucination Hallucination, auditory Page 11

12 METHYLPHENIDATE HYDROCHLORIDE Layer 3 of 8 Psychiatric disorders Hallucination, visual 1 Renal and urinary disorders Respiratory, thoracic and mediastinal disorders Thinking abnormal Mania Affect lability Inappropriate affect Anger Crying Emotional disorder Emotional distress Mood altered Mood swings Apathy Aggression Asocial behaviour Disturbance in social behaviour Paranoia Social avoidant behaviour Abnormal behaviour Psychiatric symptom Drug dependence Withdrawal syndrome Psychotic disorder Insomnia Abnormal sleep-related event Nightmare Sleep disorder Intentional self-injury Self injurious behaviour Suicidal ideation Suicide attempt Renal failure acute Pollakiuria Polyuria Wheezing Pulmonary embolism Page 12

13 METHYLPHENIDATE HYDROCHLORIDE Layer 3 of 8 Respiratory, thoracic and mediastinal disorders Dyspnoea Skin and subcutaneous tissue disorders Social circumstances Surgical and medical procedures Vascular disorders Cough Pharyngolaryngeal pain Stridor Epistaxis Angioedema Urticaria Erythema multiforme Stevens-Johnson syndrome Skin lesion Swelling face Rash erythematous Pruritus Rash Rash maculo-papular Alopecia Cold sweat Hyperhidrosis Henoch-Schonlein purpura Physical assault Pharmaceutical product compla Therapy regimen changed Peripheral ischaemia Hypotension Flushing Pallor Hypertension Page 13

14 ATTENTA Layer 4 of 8 ALL REPORT DATES Causality Unclear Exclud Total Sole Suspected - Cases Including Medicine - Occurrences of Medicine - Reactions Related to Medicine Cardiac disorders Gastrointestinal disorders General disorders and administration site conditions Investigations Metabolism and nutrition disorders Nervous system disorders Psychiatric disorders Renal and urinary disorders Skin and subcutaneous tissue disorders Tachycardia Gastrointestinal inflammation Abdominal pain Vomiting Chest discomfort Pain Drug ineffective Blood pressure increased Polydipsia Migraine Agitation Depression Aggression Abnormal behaviour Polyuria Angioedema Hyperhidrosis Page 14

15 Concerta Layer 5 of 8 ALL REPORT DATES Causality Unclear Exclud Total Sole Suspected - Cases Including Medicine - Occurrences of Medicine - Reactions Related to Medicine Congenital, familial and genetic disorders General disorders and administration site conditions Investigations Metabolism and nutrition disorders Musculoskeletal and connective tissue disorders Nervous system disorders Psychiatric disorders Skin and subcutaneous tissue disorders Tourette's disorder Condition aggravated Drug ineffective Weight increased Anorexia Muscle twitching Headache Dyskinesia Dystonia Hyperaesthesia Obsessive thoughts Fear Head banging Tic Logorrhoea Hallucination Anger Emotional disorder Mood swings Aggression Disturbance in social behaviour Paranoia Insomnia Self injurious behaviour Skin lesion Hyperhidrosis Henoch-Schonlein purpura Page 15

16 METHYLPHENIDATE HYDROCHLORIDE Layer 6 of 8 ALL REPORT DATES Causality Unclear Exclud Total Sole Suspected - Cases Including Medicine - Occurrences of Medicine - Reactions Related to Medicine Eye disorders General disorders and administration site conditions Injury, poisoning and procedural complications Investigations Musculoskeletal and connective tissue disorders Nervous system disorders Psychiatric disorders Respiratory, thoracic and mediastinal disorders Photophobia Abasia Drug interaction Drug ineffective Wrong drug administered Bleeding time prolonged Corneal reflex decreased Muscle twitching Muscle rigidity Headache Dyskinesia Extrapyramidal disorder Dystonia Tremor Hyperaesthesia Paraesthesia Dysarthria Hypertonia Anxiety Tic Depression Hallucination, auditory Anger Emotional distress Paranoia Pulmonary embolism Dyspnoea Page 16

17 RITALIN Layer 7 of 8 ALL REPORT DATES Causality Unclear Excluded Total Death Outcome Sole Suspected - Cases Including Medicine - Occurrences of Medicine - Reactions Related to Medicine Blood and lymphatic system disorders Cardiac disorders Eye disorders Gastrointestinal disorders Anaemia Aplastic anaemia Pancytopenia Tachycardia Cardiac arrest Ventricular fibrillation Palpitations Myocardial infarction Cardiomyopathy Eye oedema Eye pain Conjunctivitis Oculogyric crisis Photophobia Optic atrophy Retinal pigmentation Vision blurred Tooth discolouration Gingival hyperplasia Pancreatitis Diarrhoea Abdominal pain Abdominal pain upper Abdominal discomfort Nausea Vomiting Duodenal scarring Lip swelling Page 17

18 RITALIN Layer 7 of 8 Gastrointestinal disorders Mouth ulceration 0 General disorders and administration site conditions Infections and infestations Injury, poisoning and procedural complications Investigations Metabolism and nutrition disorders Musculoskeletal and connective tissue disorders Pyrexia Sudden death Fatigue Chest discomfort Feeling abnormal Influenza like illness Irritability Swelling Face oedema Oedema peripheral Chest pain Pain Drug interaction Drug effect decreased Drug ineffective Mass Otitis media Infection Pharyngitis Rhinitis Viral infection Fall Electrocardiogram abnormal Heart rate increased Androgens increased Prothrombin level decreased Weight decreased Anorexia Decreased appetite Polydipsia Pain in jaw Myalgia Muscle twitching Growth retardation Page 18

19 RITALIN Layer 7 of 8 Neoplasms benign, malignant and unspecified (incl cysts and polyps) Pseudolymphoma Neoplasm malignant 0 1 Nervous system disorders Psychiatric disorders Optic neuritis Headache Dementia Amnesia Dyskinesia Extrapyramidal disorder Hyperkinesia Tardive dyskinesia Dystonia Tremor Ataxia Coma Lethargy Somnolence Dizziness Formication Dysgeusia Visual field defect Hypertonia Neuroleptic malignant syndrom Poor quality sleep Neurosis Obsessive-compulsive disorder Agitation Anxiety Nervousness Restlessness Tic Distractibility Confusional state Depression Tearfulness Hallucination Page 19

20 RITALIN Layer 7 of 8 Psychiatric disorders Thinking abnormal 1 Renal and urinary disorders Respiratory, thoracic and mediastinal disorders Skin and subcutaneous tissue disorders Mania Inappropriate affect Crying Apathy Aggression Asocial behaviour Paranoia Social avoidant behaviour Drug dependence Withdrawal syndrome Psychotic disorder Insomnia Abnormal sleep-related event Nightmare Sleep disorder Suicidal ideation Suicide attempt Renal failure acute Pollakiuria Polyuria Dyspnoea Cough Pharyngolaryngeal pain Stridor Angioedema Urticaria Erythema multiforme Stevens-Johnson syndrome Swelling face Rash erythematous Pruritus Rash Rash maculo-papular Alopecia Page 20

21 RITALIN Layer 7 of 8 Skin and subcutaneous tissue disorders Cold sweat 1 Social circumstances Vascular disorders Hyperhidrosis Physical assault Peripheral ischaemia Hypotension Flushing Pallor Hypertension Page 21

22 Ritalin LA Layer 8 of 8 ALL REPORT DATES Causality Unclear Exclud Total Sole Suspected - Cases Including Medicine - Occurrences of Medicine - Reactions Related to Medicine Blood and lymphatic system disorders Cardiac disorders Endocrine disorders Eye disorders Gastrointestinal disorders General disorders and administration site conditions Investigations Metabolism and nutrition disorders Musculoskeletal and connective tissue disorders Anaemia Arrhythmia Tachycardia Palpitations Hypothyroidism Vision blurred Visual disturbance Diarrhoea Abdominal pain upper Nausea Vomiting Dry mouth Fatigue Malaise Feeling abnormal Pain Drug ineffective Drug withdrawal syndrome Electrocardiogram abnormal Heart rate increased Heart rate irregular Intraocular pressure increased Weight increased Anorexia Increased appetite Obesity Muscle twitching Sensation of heaviness Page 22

23 Ritalin LA Layer 8 of 8 Nervous system disorders Headache 4 4 Psychiatric disorders Respiratory, thoracic and mediastinal disorders Skin and subcutaneous tissue disorders Choreoathetosis Psychomotor hyperactivity Tremor Lethargy Somnolence Dizziness Agitation Anxiety Nervousness Panic attack Tic Lack of spontaneous speech Confusional state Disorientation Depression Hallucination Hallucination, visual Affect lability Anger Crying Mood altered Abnormal behaviour Psychiatric symptom Withdrawal syndrome Psychotic disorder Intentional self-injury Wheezing Epistaxis Urticaria Pruritus Rash Rash maculo-papular Cold sweat Hyperhidrosis Page 23

24 Ritalin LA Layer 8 of 8 Social circumstances Pharmaceutical product compla Surgical and medical procedures Therapy regimen changed Page 24

MEDICINE SUMMARY. CHLORPROMAZINE HYDROCHLORIDE Layer 1 of 1 ALL REPORT DATES. Febrile neutropenia. Lymphadenopathy. Thrombocythaemia.

MEDICINE SUMMARY. CHLORPROMAZINE HYDROCHLORIDE Layer 1 of 1 ALL REPORT DATES. Febrile neutropenia. Lymphadenopathy. Thrombocythaemia. ALL REPORT DATES Causality Unclear Excluded Total Death Outcome Sole Suspected - Cases Including Medicine - Occurrences of Medicine - Reactions Related to Medicine Blood and lymphatic system disorders

More information

Medicine summary - Antipsychotics- haloperidol

Medicine summary - Antipsychotics- haloperidol 748 22 330 Blood and lymphatic system disorders Anaemia 2 0 0 Bone marrow failure 1 0 0 Pancytopenia 4 0 1 Haemolytic anaemia 1 0 0 Thrombocytopenia 2 0 0 Lymphadenopathy 1 0 0 Splenomegaly 2 0 0 Eosinophilia

More information

Medicine summary - Antipsychotics- chlorpromazine

Medicine summary - Antipsychotics- chlorpromazine 591 21 241 Blood and lymphatic system disorders Anaemia 3 0 0 Aplastic anaemia 3 1 0 Pancytopenia 2 1 1 Thrombocytopenia 6 1 1 Thrombocytosis 1 0 0 Lymphadenopathy 3 1 1 Eosinophilia 5 0 0 Leukocytosis

More information

Case Series Drug Analysis Print Name: Vaxigrip, Fluarix, Inflexal V og Influenzacvaccine 01Sep Oct2014

Case Series Drug Analysis Print Name: Vaxigrip, Fluarix, Inflexal V og Influenzacvaccine 01Sep Oct2014 - 16Oct2014 Report Run Date: 20-Oct-2014 Data Lock Date: 16-Oct-2014 19:00:06 Earliest Reaction Date: 28-Oct-2009 MedDRA Version: MedDRA 17.0 Vaxigrip, Fluarix, Inflexal V og Influenzacvaccine : Alle cases

More information

Suspected Adverse Reaction Analysis. CERVARIX Human papillomavirus (HPV) vaccine

Suspected Adverse Reaction Analysis. CERVARIX Human papillomavirus (HPV) vaccine Suspected Adverse Reaction Analysis CERVARIX Human papillomavirus (HPV) vaccine 2 May 2009 This report summarises the adverse reactions suspected to have been caused by Cervarix human papillomavirus (HPV)

More information

Database of Adverse Event Notifications - medicines

Database of Adverse Event Notifications - medicines Database of Adverse Event Notifications - medicines You searched for the following 3 medicines between 01/01/2017 01/01/2018: Ferinject 100mg/2mL (Ferric carboxymaltose) Ferinject 500mg/10mL (Ferric carboxymaltose)

More information

Summary listing of suspected adverse reactions and events associated with use of Gardasil 01/06/ /12/2015

Summary listing of suspected adverse reactions and events associated with use of Gardasil 01/06/ /12/2015 1 2015-023780 2015-023788 2015-023805 2015-023819 2015-023820 2015-023821 Injection site swelling Transient immobility Abdominal pain Visual acuity reduced Chronic fatigue syndrome Mental disorder Pallor

More information

Summary details of suspected adverse reactions/events associated with the use of Gardasil 1st March st March 2015

Summary details of suspected adverse reactions/events associated with the use of Gardasil 1st March st March 2015 Page 1 of 6 Adverse (s) Date Outcome 2014-019844 04/03/2014 13 Years Prophylaxis GARDASIL 04/12/2013 Nausea 04/12/2013 06/12/2013 Headache 04/12/2013 06/12/2013 Vomiting 04/12/2013 06/12/2013 Asthenia

More information

Case Series Drug Analysis Print Name: Isotretinoin

Case Series Drug Analysis Print Name: Isotretinoin Report Run Date: 30-Dec-2013 Data Lock Date: 27-Dec-2013 23:09:23 Earliest Reaction Date: 12-Jun-1997 MedDRA Version: MedDRA 16.1 Isotretinoin: No description provided. Report Run Date: 30-Dec-2013, Page

More information

Medicine summary - citalopram (to end January 2009)

Medicine summary - citalopram (to end January 2009) 734 13 493 Blood and lymphatic system disorders Iron deficiency anaemia 1 0 1 Anaemia 1 0 1 Pancytopenia 2 0 0 Thrombocytopenia 3 0 2 Lymphadenopathy 1 0 1 Eosinophilia 2 0 1 Leukocytosis 1 0 0 Leukopenia

More information

Lessons learnt from Influenza A(H1N1) vaccines benefit-risk monitoring

Lessons learnt from Influenza A(H1N1) vaccines benefit-risk monitoring Lessons learnt from Influenza A(H1N1) vaccines benefit-risk monitoring ENCePP Plenary meeting Xavier Kurz 8 June 20 An agency of the European Union Contents 1. Safety database at time of authorisation

More information

Adverse events following immunisation (AEFI) with 2010/2011 seasonal influenza vaccines

Adverse events following immunisation (AEFI) with 2010/2011 seasonal influenza vaccines Adverse events following immunisation (AEFI) with 00/0 seasonal influenza vaccines Netherlands Pharmacovigilance Centre Lareb 8 juli 0 Goudsbloemvallei 7 57 MH s-hertogenbosch www.lareb.nl info@lareb.nl

More information

Nausicalm solution for injection is a clear colourless solution, presented in 1 ml ampoules.

Nausicalm solution for injection is a clear colourless solution, presented in 1 ml ampoules. Nausicalm Cyclizine lactate 50 mg/ml solution for injection Presentation Nausicalm solution for injection is a clear colourless solution, presented in 1 ml ampoules. Uses Actions Cyclizine is a piperazine

More information

Study No.: Title: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Core Safety Profile. Pharmaceutical form(s)/strength: Capsules, 0.5 mg AT/H/PSUR/0028/001 Date of FAR:

Core Safety Profile. Pharmaceutical form(s)/strength: Capsules, 0.5 mg AT/H/PSUR/0028/001 Date of FAR: Core Safety Profile Active substance: Anagrelide hydrochloride Pharmaceutical form(s)/strength: Capsules, 0.5 mg P-RMS: AT/H/PSUR/0028/001 Date of FAR: 02.08.2010 4.3 Contraindications Hypersensitivity

More information

Core Safety Profile. Pharmaceutical form(s)/strength: Immediate release tablets 1 mg, 2 mg, 4 mg and 8 mg (IR) Date of FAR:

Core Safety Profile. Pharmaceutical form(s)/strength: Immediate release tablets 1 mg, 2 mg, 4 mg and 8 mg (IR) Date of FAR: Core Safety Profile Active substance: Doxazosin Pharmaceutical form(s)/strength: Immediate release tablets 1 mg, 2 mg, 4 mg and 8 mg (IR) P - RMS: DK/H/PSUR/0004/002 Date of FAR: 12.12.2011 4.3 Contraindications

More information

MabThera. SC. The wait is over. MabThera delivered in just 5 minutes. SC= subcutaneous injection

MabThera. SC. The wait is over. MabThera delivered in just 5 minutes. SC= subcutaneous injection MabThera SC. The wait is over. MabThera delivered in just 5 minutes Abbreviated Prescribing Information MabThera 1400 mg solution for subcutaneous (SC) injection (Rituximab) Indications: Indicated in adults

More information

Core Safety Profile. Pharmaceutical form(s)/strength: Sterile eye drops 1%, 2% Date of FAR:

Core Safety Profile. Pharmaceutical form(s)/strength: Sterile eye drops 1%, 2% Date of FAR: Core Safety Profile Active substance: Carteolol Pharmaceutical form(s)/strength: Sterile eye drops 1%, 2% P - RMS: SK/H/PSUR/0002/002 Date of FAR: 16.03.2012 4.1 THERAPEUTIC INDICATIONS Ocular hypertension

More information

PFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See United States Package Insert (USPI)

PFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See United States Package Insert (USPI) PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.

More information

U.S. Department of Health and Human Services Food and Drug Administration Center for Food Safety and Applied Nutrition

U.S. Department of Health and Human Services Food and Drug Administration Center for Food Safety and Applied Nutrition U.S. Department of Health and Human Services Food and Drug Administration Center for Food Safety and Applied Nutrition CFSAN Adverse Event Reporting System Voluntary and Mandatory Reports on 5-Hour Energy,

More information

GLOSSARY OF MEDICAL TERMS IN LAY LANGUAGE

GLOSSARY OF MEDICAL TERMS IN LAY LANGUAGE GLOSSARY OF MEDICAL TERMS IN LAY LANGUAGE The CSM Working Group on Patient Information recognises that users may not be familiar with the terms used in patient information leaflets to describe unwanted

More information

Pharmaceutical form(s)/strength: Solution: 5 mg/ml Suspensions: 2.5 and 5 mg/ml P-RMS:

Pharmaceutical form(s)/strength: Solution: 5 mg/ml Suspensions: 2.5 and 5 mg/ml P-RMS: 0BCore Safety Profile Active substance: Betaxolol eyedrops Pharmaceutical form(s)/strength: Solution: 5 mg/ml Suspensions: 2.5 and 5 mg/ml P-RMS: HU/H/PSUR/0010/002 Date of FAR: 20.03.2013 4.2 Posology

More information

Nilotinib AEs (adverse events) in CML population:

Nilotinib AEs (adverse events) in CML population: Nilotinib AEs (adverse events) in CML population: The percentages below were taken from a randomized trial of nilotinib 300mg BID in newly diagnosed Ph+ CML patients (N=279) taken from the Tasigna 2017

More information

CORE SAFETY PROFILE OXYCODONE HYDROCHLORIDE NL/H/PSUR/0054/ January 2013

CORE SAFETY PROFILE OXYCODONE HYDROCHLORIDE NL/H/PSUR/0054/ January 2013 CORE SAFETY PROFILE OXYCODONE HYDROCHLORIDE NL/H/PSUR/0054/001 16 January 2013 1 4.2 Posology and method of administration (safety aspects only) Posology Elderly patients For oral preparations A dose adjustment

More information

Medication is just part of the management of these illnesses. Other therapies are also helpful; you may wish to discuss these with your prescriber.

Medication is just part of the management of these illnesses. Other therapies are also helpful; you may wish to discuss these with your prescriber. Know Your Medicines Duloxetine The purpose of this leaflet is to give you some general information on duloxetine, and is intended as a guide only. This should be read in conjunction with the official patient

More information

Pharmaceutical form(s)/strength: Powder for solution for injection/prefilled syringe, 20mg UK/H/PSUR/0027/002 Date of FAR:

Pharmaceutical form(s)/strength: Powder for solution for injection/prefilled syringe, 20mg UK/H/PSUR/0027/002 Date of FAR: M0BCore Safety Profile Active substance: Glatiramer Pharmaceutical form(s)/strength: Powder for solution for injection/prefilled syringe, 20mg P-RMS: UK/H/PSUR/0027/002 Date of FAR: 20.03.2013 4.2 Posology

More information

Continence PGD - Oxybutynin 5mg Modified Release

Continence PGD - Oxybutynin 5mg Modified Release Continence PGD - Oxybutynin 5mg Modified Release Patient group direction for the supply of Oxybutynin Lyrinel XL 5mg and 10mg tablets, maximum dose of 20mg/day to patients suffering from urinary frequency,

More information

Database of Adverse Event Notifications - medicines

Database of Adverse Event Notifications - medicines Database of Adverse Event Notifications - medicines You searched for the following 2 medicines between 01/01/2000 18/10/2017: Invokana (Canagliflozin) Not specified (Canagliflozin) Commonwealth of Australia

More information

CECILIA P MARGRET MD PhD MPH Child, Adolescent and Adult Psychiatry NE 24th ST Suite 104, Bellevue WA 98007, Phone / Fax: +1 (425)

CECILIA P MARGRET MD PhD MPH Child, Adolescent and Adult Psychiatry NE 24th ST Suite 104, Bellevue WA 98007, Phone / Fax: +1 (425) IDENTIFYING INFORMATION PATIENT INFORMATION FORM Patient's Name: DOB: Ethnicity/race: Gender: Primary language if other than English: Address: Phone: Home/ Mobile/ Work Email: Occupation: Marital Status:

More information

Public Case Detail. Case Number : Reaction : Medicine details : Cases Count: 15. Gender : Weight (kg) : 36Y. Hospitalisation : Age :

Public Case Detail. Case Number : Reaction : Medicine details : Cases Count: 15. Gender : Weight (kg) : 36Y. Hospitalisation : Age : Case Number : 231711 9/8/27 M 36Y Unknown Urticaria Reason : Tablet 4 Milligram 2 times Oral CITALOPRAM HYDROBROMIDE (Other drug) Reason : 4 Milligram Oral PUTRAN2 Page 1 of 18 Case Number : 233954 M 3/1/27

More information

Cetirizine Proposed Core Safety Profile

Cetirizine Proposed Core Safety Profile Cetirizine Proposed Core Safety Profile Posology and method of administration Elderly subjects: data do not suggest that the dose needs to be reduced in elderly subjects provided that the renal function

More information

Sponsor. Generic Drug Name. Trial Indications. Protocol Number. Protocol Title. Clinical Trial Phase. Study Start/End Dates. Reason for Termination

Sponsor. Generic Drug Name. Trial Indications. Protocol Number. Protocol Title. Clinical Trial Phase. Study Start/End Dates. Reason for Termination Sponsor Alcon Research, Ltd. Generic Drug Name Travoprost/timolol maleate Trial Indications Open-angle glaucoma or ocular hypertension Protocol Number C-09-007 Protocol Title An Evaluation of Patient Reported

More information

Please list any treatments you have previously had for current illness. (Physical Therapy, Surgery, Radiation, etc.)

Please list any treatments you have previously had for current illness. (Physical Therapy, Surgery, Radiation, etc.) Date: Patient Name: D.O.B Last First M.I History of Present Illness: What is the reason for your visit? Date symptom started? Please list any treatments you have previously had for current illness. (Physical

More information

Complete the CE Checklist for Customized Symptoms. Page 1 of 6

Complete the CE Checklist for Customized Symptoms. Page 1 of 6 Progress Tracking Complete the CE Checklist for Customized Symptoms Page 1 of 6 Generic Positive Symptom Tracking Concentration Quality Of Sleep Motivation/Energy Patience Short Term Memory Appetite Positive

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER

PACKAGE LEAFLET: INFORMATION FOR THE USER PACKAGE LEAFLET: INFORMATION FOR THE USER 250 mg film-coated tablets. 500 mg film-coated tablets. 750 mg film-coated tablets. 1000 mg film-coated tablets. Levetiracetam

More information

Package leaflet: Information for the user. LETROKS, 2,5 mg, film-coated tablets Letrozolum

Package leaflet: Information for the user. LETROKS, 2,5 mg, film-coated tablets Letrozolum Package leaflet: Information for the user LETROKS, 2,5 mg, film-coated tablets Letrozolum Read all of this leaflet carefully before you start taking this medicine because it contains important information

More information

Efficacy Study of Zoledronic Acid and Teriparatide Combination Therapy in Women With Osteoporosis

Efficacy Study of Zoledronic Acid and Teriparatide Combination Therapy in Women With Osteoporosis A service of the U.S. National Institutes of Health Trial record 1 of 1 for: CZOL446H2409 Previous Study Return to List Next Study Efficacy Study of Zoledronic Acid and Combination Therapy in Women With

More information

Core Safety Profile. Pharmaceutical form(s)/strength: Prolonged release tablets, 4 mg and 8 mg (GITS) Date of FAR:

Core Safety Profile. Pharmaceutical form(s)/strength: Prolonged release tablets, 4 mg and 8 mg (GITS) Date of FAR: Core Safety Profile Active substance: Doxazosin Pharmaceutical form(s)/strength: Prolonged release tablets, 4 mg and 8 mg (GITS) P - RMS: DK/H/PSUR/0004/002 Date of FAR: 12.12.2011 4.3 Contraindications

More information

Carboplatin / Liposomal Doxorubicin CARBO/CAELYX Gynaecological Cancer

Carboplatin / Liposomal Doxorubicin CARBO/CAELYX Gynaecological Cancer Systemic Anti Cancer Treatment Protocol Carboplatin / CARBO/CAELYX Gynaecological Cancer PROCTOCOL REF: MPHAGYNCCX (Version No: 1.0) Approved for use in: Advanced ovarian cancer in women who have progressed

More information

Core Safety Profile. Pharmaceutical form(s)/strength: Capsules, Tablets / 5 mg, 10 mg ES/H/PSUR/0013/001 Date of FAR:

Core Safety Profile. Pharmaceutical form(s)/strength: Capsules, Tablets / 5 mg, 10 mg ES/H/PSUR/0013/001 Date of FAR: Core Safety Profile Active substance: Flunarizine Pharmaceutical form(s)/strength: Capsules, Tablets / 5 mg, 10 mg P RMS: ES/H/PSUR/0013/001 Date of FAR: 13.12.2010 4.3 Contraindications Flunarizine is

More information

1.1. An overview of reports on agomelatine

1.1. An overview of reports on agomelatine 1.1. An overview of reports on agomelatine Introduction Agomelatine (Valdoxan ) was registered for the European market on February 19th 2009 and is indicated for treatment of major depressive episodes

More information

Synopsis Style Clinical Study Report SR EFC10139 Version number: 1 (electronic 2.0)

Synopsis Style Clinical Study Report SR EFC10139 Version number: 1 (electronic 2.0) SYNOPSIS Title of the study: A randomized, double-blind, parallel-group, multicenter, multinational study to assess the long-term effect, over 1 year, of rimonabant 10 mg in comparison with rimonabant

More information

Continence PGD transdermal oxybutynin Kentera patch 36mg

Continence PGD transdermal oxybutynin Kentera patch 36mg Continence PGD transdermal oxybutynin Kentera patch 36mg Patient group direction for the supply of transdermal oxybutynin Kentera patch 36mg to patients suffering from urinary frequency, urgency or incontinence

More information

M0BCore Safety Profile. Active substance: Bromazepam Pharmaceutical form(s)/strength: Tablets 6 mg FR/H/PSUR/0066/001 Date of FAR:

M0BCore Safety Profile. Active substance: Bromazepam Pharmaceutical form(s)/strength: Tablets 6 mg FR/H/PSUR/0066/001 Date of FAR: M0BCore Safety Profile Active substance: Bromazepam Pharmaceutical form(s)/strength: Tablets 6 mg P-RMS: FR/H/PSUR/0066/001 Date of FAR: 26.11.2013 4.3 Contraindications Bromazepam must not be administered

More information

Search for studies: ClinicalTrials.gov Identifier: NCT

Search for studies: ClinicalTrials.gov Identifier: NCT ClinicalTrials.gov A service of the U.S. National Institutes of Health Search for studies: Example. "Heart attack" AND "Los Angeles" Advanced Search Help Studies by Topic Glossary Find Studies About Clinical

More information

Presenter. Dr. Ronald Lucchino

Presenter. Dr. Ronald Lucchino Adverse Drug Reactions in Adults with Down Syndrome Presenter Dr. Ronald Lucchino rvluc@comcast.net PURPOSE To increase staff awareness that older adults with DD may have higher levels of medication in

More information

Drugs for Emotional and Mood Disorders Chapter 16

Drugs for Emotional and Mood Disorders Chapter 16 Drugs for Emotional and Mood Disorders Chapter 16 NCLEX-RN Review Question 1 Choices Please note Question #1 at the end of Ch 16 pg 202 & Key pg 805 answer is #4 1. Psychomotor symptoms 2. Tachycardia,

More information

Package leaflet: Information for the user. Cetiristad 10 mg film-coated tablets Cetirizine dihydrochloride

Package leaflet: Information for the user. Cetiristad 10 mg film-coated tablets Cetirizine dihydrochloride Package leaflet: Information for the user Cetiristad 10 mg film-coated tablets Cetirizine dihydrochloride Read all of this leaflet carefully before you start taking this medicine because it contains important

More information

Medical History Form

Medical History Form General: Medical History Form 1. Chief Complaint: What are the main health concerns you wish to address? 2. Current and Past Treatment: Have you received treatment for these problems? Yes No, if yes, which:

More information

Liposomal Doxorubicin (CAELYX) Gynaecological Cancer

Liposomal Doxorubicin (CAELYX) Gynaecological Cancer Systemic Anti Cancer Treatment Protocol Liposomal Doxorubicin (CAELYX) Gynaecological Cancer PROCTOCOL REF: OPHAGYNCAE (Version No: 1.0) Approved for use in: Advanced ovarian cancer second/third line treatment

More information

Joseph S. Weiner, MD, PC Patient History Form

Joseph S. Weiner, MD, PC Patient History Form Date: / / NAME: Last First M. I. Age: Sex: q F q M Birthdate: / / What specific questions or goals do you have for this appointment? Please list the names of other clinicians you have seen for this problem:

More information

M0BCore Safety Profile

M0BCore Safety Profile M0BCore Safety Profile Active substance: Aztreonam Pharmaceutical form(s)/strength: 500 mg, 1 g and 2 g powder for solution for injection and infusion NB! 75mg aztreonam for nebulisation to treat infections

More information

+ Color Change - + Hearing Loss - + Apnea - + Enuresis (urine - + Tremors - + Rash -

+ Color Change - + Hearing Loss - + Apnea - + Enuresis (urine - + Tremors - + Rash - Review of Systems: 0-1 year old Constitution neg Eyes neg GI neg Neurological neg + Activity Change - + Eye Discharge - + Reflux - + Facial Asymmetry - + Appetite Change - + Eye Redness - + Vomiting -

More information

Public Case Detail. Causality probable Recovered. Changed to Ritalin LA 40 mg and Ritalin 20 mg and has been fine since

Public Case Detail. Causality probable Recovered. Changed to Ritalin LA 40 mg and Ritalin 20 mg and has been fine since Case Number : 195519 16/03/2004 66 18/12/1987 Causality probable Recovered Changed to Ritalin LA 40 mg and Ritalin 20 mg and has been fine since Headache Headaches, sweating, mood swings, not eating. Ceased

More information

Core Safety Profile Triptorelin 1-month/3-month formulation ATC-code: L02A E 04 March 2010

Core Safety Profile Triptorelin 1-month/3-month formulation ATC-code: L02A E 04 March 2010 Core Safety Profile Triptorelin 1-month/3-month formulation ATC-code: L02A E 04 March 2010 4.3 Contraindications Hypersensitivity to GnRH, its analogues or any other component of the medicinal product

More information

Venlafaxine hydrochloride extended-release and other antidepressant medicines may cause serious side effects, including:

Venlafaxine hydrochloride extended-release and other antidepressant medicines may cause serious side effects, including: Medication Guide VENLAFAXINE XR (venlafaxine hydrochloride) (Extended-Release Capsules) Read the Medication Guide that comes with venlafaxine hydrochloride extended-release before you start taking it and

More information

Pharmaceutical form(s)/strength: Capsules, 200mg, 400mg, Oral suspensions, 90mg/5ml, 180mg/5ml, 36 mg/ml SI/H/PSUR/0002/002 Date of FAR:

Pharmaceutical form(s)/strength: Capsules, 200mg, 400mg, Oral suspensions, 90mg/5ml, 180mg/5ml, 36 mg/ml SI/H/PSUR/0002/002 Date of FAR: 0BCore Safety Profile Active substance: Ceftibuten Pharmaceutical form(s)/strength: Capsules, 200mg, 400mg, Oral suspensions, 90mg/5ml, 180mg/5ml, 36 mg/ml P-RMS: SI/H/PSUR/0002/002 Date of FAR: 14.02.2013

More information

Azathioprine toxicity criteria and severity descriptors for the listing of biological agents for rheumatoid arthritis on the PBS

Azathioprine toxicity criteria and severity descriptors for the listing of biological agents for rheumatoid arthritis on the PBS Azathioprine toxicity criteria and severity descriptors for the listing of biological agents for rheumatoid arthritis on the PBS Only valid for adult patients Azathioprine must be at a dose of at least

More information

2014 NATIONAL COVERAGE DETERMINATION (NCD) CPT CODE(S): 84436, 84439, 84443, THYROID TESTING DESCRIPTION

2014 NATIONAL COVERAGE DETERMINATION (NCD) CPT CODE(S): 84436, 84439, 84443, THYROID TESTING DESCRIPTION 017.50-017.56 Tuberculosis of the thyroid gland 183.0 Malignant neoplasm of ovary 193 Malignant neoplasm of thyroid gland 194.8 Malignant neoplasm of other endocrine glands and related structures 198.89

More information

1.1. An overview of reports on sitagliptin

1.1. An overview of reports on sitagliptin 1.1. An overview of reports on Introduction Sitagliptin (Januvia ) was registered for the European marked on March 21 st 27 with the Netherlands as rapporteur. It is indicated as treatment of for patients

More information

P-RMS: FR/H/PSUR/0036/001

P-RMS: FR/H/PSUR/0036/001 Core Safety Profile Active substance: Alprazolam Pharmaceutical form(s)/strength: Tablet uncoated, sugar coated, film coated, 0.25mg Tablet uncoated, 0.4 mg Tablet uncoated, sugar coated, film coated,

More information

Package leaflet: Information for the patient. Cetirizin Sandoz 10 mg film-coated tablets. cetirizine dihydrochloride

Package leaflet: Information for the patient. Cetirizin Sandoz 10 mg film-coated tablets. cetirizine dihydrochloride Package leaflet: Information for the patient Cetirizin Sandoz 10 mg film-coated tablets cetirizine dihydrochloride [For medicine available only on prescription:] Read all of this leaflet carefully before

More information

Summary of risk management plan for Methylphenidate modifiedrelease hard capsules (methylphenidate)

Summary of risk management plan for Methylphenidate modifiedrelease hard capsules (methylphenidate) Part VI: Summary of the risk management plan Summary of risk management plan for Methylphenidate modifiedrelease hard capsules (methylphenidate) This is a summary of the risk management plan (RMP) for

More information

Core Safety Profile. Pharmaceutical form(s)/strength: Tablets and Oral lyophilisates (wafers) 5 and 10 mg NL/H/PSUR/0002/001 Date of FAR:

Core Safety Profile. Pharmaceutical form(s)/strength: Tablets and Oral lyophilisates (wafers) 5 and 10 mg NL/H/PSUR/0002/001 Date of FAR: Core Safety Profile Active substance: Rizatriptan Pharmaceutical form(s)/strength: Tablets and Oral lyophilisates (wafers) 5 and 10 mg P RMS: NL/H/PSUR/0002/001 Date of FAR: 23.05.2011 4.3 Contraindications

More information

6.1 CARDIAC DRUGS AGENT FOR CONGESTIVE HEART FAILURE

6.1 CARDIAC DRUGS AGENT FOR CONGESTIVE HEART FAILURE 6.1 CARDIAC DRUGS 6.1.1 AGENT FOR CONGESTIVE HEART FAILURE - 36 - GROUP 6 DIGOXIN Indication: Treatment of congestive heart failure and to slow the ventricular rate in tachyarrhythmias such as atrial fibrillation,

More information

UK Suspected Adverse Drug Reaction (ADR) Analysis

UK Suspected Adverse Drug Reaction (ADR) Analysis UK Suspected Adverse Drug Reaction (ADR) Analysis Influenza antivirals - oseltamivir (Tamiflu) and zanamivir (Relenza) 26 th November 2009 This report summarises all UK reports of suspected adverse drug

More information

M0BCore Safety Profile

M0BCore Safety Profile M0BCore Safety Profile Active substance: Clostridium botulinum neurotoxin type A haemagglutinin complex Pharmaceutical form(s)/strength: powder for solution for injection, 300 unit and 500 unit P-RMS:

More information

PATIENT HEALTH QUESTIONNAIRE Radiation Oncology

PATIENT HEALTH QUESTIONNAIRE Radiation Oncology REVIEWED DATE / INITIALS Safety: Yes No Are you at risk for falls? Do you have a Pacemaker? Females; Is there a possibility you may be pregnant? Allergies: Yes No If YES, please list medication allergies:

More information

V F 4 Years N Recovered DT FEVER INJECTION SITE REACTION

V F 4 Years N Recovered DT FEVER INJECTION SITE REACTION * CAVEAT: The vast majority of reports on which this summary is based are submitted by health practitioners. Each report represents the suspicion, opinion or observation of the individual reporter. Cause

More information

Overview of reports of adverse drug reactions associated with changes of the package of Thyrax (levothyroxine) from a bottle to a blister

Overview of reports of adverse drug reactions associated with changes of the package of Thyrax (levothyroxine) from a bottle to a blister Overview of reports of adverse reactions associated with changes of the package of from a bottle to a blister Introduction The was granted marketing authorization in the Netherlands on 6 June, 1980. Levothyroxine

More information

Core Safety Profile. Pharmaceutical form(s)/strength: Film-coated tablets 1.25 mg, 2.5 mg, 3.75 mg, 5 mg, 7.5 mg and 10 mg. Date of FAR:

Core Safety Profile. Pharmaceutical form(s)/strength: Film-coated tablets 1.25 mg, 2.5 mg, 3.75 mg, 5 mg, 7.5 mg and 10 mg. Date of FAR: Core Safety Profile Active substance: Bisoprolol Pharmaceutical form(s)/strength: Film-coated tablets 1.25 mg, 2.5 mg, 3.75 mg, 5 mg, 7.5 mg and 10 mg P - RMS: FI/H/PSUR/0002/002 Date of FAR: 13.12.2011

More information

patient group direction

patient group direction CYCLIZINE v01 1/7 CYCLIZINE PGD Details Version 1.0 Legal category Staff grades Approved by POM Paramedic (Non-ECP) Nurse (Non-ECP) Emergency Care Practitioner (Paramedic) Emergency Care Practitioner (Nurse)

More information

Pharmaceutical form(s)/strength: 50, 100, 200, 400 mg tablets P-RMS:

Pharmaceutical form(s)/strength: 50, 100, 200, 400 mg tablets P-RMS: 0BCore Safety Profile Active substance: Amisulpride Pharmaceutical form(s)/strength: 50, 100, 200, 400 mg tablets P-RMS: IE/H/PSUR/0017/002 Date of FAR: 28.11.2012 Core Safety Profile [amisulpride] Formulations:

More information

ANTI-DEPRESSANT MEDICATIONS

ANTI-DEPRESSANT MEDICATIONS ANTI-DEPRESSANT MEDICATIONS This information is not intended to be a substitute for medical advice. It s purpose is solely informative. If your client or yourself are taking antidepressants, do not change

More information

0BCore Safety Profile. Pharmaceutical form(s)/strength: Losec MUPS tablets 10, 20 mg (OTC) NL/H/PSUR/0058/001 Date of FAR:

0BCore Safety Profile. Pharmaceutical form(s)/strength: Losec MUPS tablets 10, 20 mg (OTC) NL/H/PSUR/0058/001 Date of FAR: 0BCore Safety Profile Active substance: Omeprazole Pharmaceutical form(s)/strength: Losec MUPS tablets 10, 20 mg (OTC) P-RMS: NL/H/PSUR/0058/001 Date of FAR: 13.06.2013 4.2 Posology and method of administration

More information

Package leaflet: Information for the user Zirtek Allergy Relief 10 mg film-coated tablets Cetirizine dihydrochloride

Package leaflet: Information for the user Zirtek Allergy Relief 10 mg film-coated tablets Cetirizine dihydrochloride Package leaflet: Information for the user Zirtek Allergy Relief 10 mg film-coated tablets Cetirizine dihydrochloride Read all of this leaflet carefully before you start taking this medicine because it

More information

Introductory Clinical Pharmacology Chapter 32 Antiparkinsonism Drugs

Introductory Clinical Pharmacology Chapter 32 Antiparkinsonism Drugs Introductory Clinical Pharmacology Chapter 32 Antiparkinsonism Drugs Dopaminergic Drugs: Actions Symptoms of parkinsonism are caused by depletion of dopamine in CNS Amantadine: makes more of dopamine available

More information

PATIENT HEALTH QUESTIONNAIRE Radiation Oncology

PATIENT HEALTH QUESTIONNAIRE Radiation Oncology REVIEWED DATE / INITIALS Safety: Are you at risk for falls? Do you have a Pacemaker? Females; Is there a possibility you may be pregnant? Allergies: If YES, please list medication allergies: Do you have

More information

Medication Guide Fluoxetine Oral Solution USP What is the most important information I should know about fluoxetine oral solution?

Medication Guide Fluoxetine Oral Solution USP What is the most important information I should know about fluoxetine oral solution? Medication Guide Fluoxetine Oral Solution USP Read the Medication Guide that comes with fluoxetine before you start taking it and each time you get a refill. There may be new information. This Medication

More information

Drug Management of Parkinsonism. By Prof. Mohammad Saleh M. Hassan PhD. (Pharma); MSc. (Ped.); MHPE (Ed.)

Drug Management of Parkinsonism. By Prof. Mohammad Saleh M. Hassan PhD. (Pharma); MSc. (Ped.); MHPE (Ed.) Drug Management of Parkinsonism By Prof. Mohammad Saleh M. Hassan PhD. (Pharma); MSc. (Ped.); MHPE (Ed.) Drug management of Parkinsonism Levodopa Ergot derivatives noamine Oxidaes Inhibitors Catechol-Omethyl

More information

Drugs used in obstetrics

Drugs used in obstetrics Drugs used in obstetrics Drugs used in obstetrics Drugs may be used to modify uterine contractions. These include oxytocic drugs used to stimulate uterine contractions both in induction of labour and to

More information

HAMILTON ANXIETY RATING SCALE (HAM-A)

HAMILTON ANXIETY RATING SCALE (HAM-A) HAMILTON ANXIETY RATING SCALE (HAM-A) Mood Disorders Psychopharmacology Unit www.mdpu.ca 1 Patient Information Patient Date Day Mth. Year Time Hour Min Personal notes 1. Anxious mood This item covers the

More information

Patient Group Direction for the supply and/or administration of Ibuprofen 400mg tablets to patients attending NHS Borders services

Patient Group Direction for the supply and/or administration of Ibuprofen 400mg tablets to patients attending NHS Borders services Patient Group Direction for the supply and/or administration of Ibuprofen 400mg tablets to patients attending NHS Borders services This document authorises the supply and/or administration of Ibuprofen

More information

Elements for a Public Summary. VI.2.1 Overview of disease epidemiology

Elements for a Public Summary. VI.2.1 Overview of disease epidemiology VI.2 Elements for a Public Summary VI.2.1 Overview of disease epidemiology Schizophrenia Schizophrenia is a mental disorder often characterized by abnormal social behaviour and failure to recognize what

More information

January 2008 IMPORTANT DRUG WARNING

January 2008 IMPORTANT DRUG WARNING January 2008 IMPORTANT DRUG WARNING Dear Healthcare Professional: Roche would like to advise you of a recent update to the PEGASYS (Peginterferon alfa-2a) and COPEGUS (Ribavirin, USP) package inserts.

More information

Core Safety Profile. Date of FAR:

Core Safety Profile. Date of FAR: Core Safety Profile Active substance: Levobupivicaine Pharmaceutical form(s)/strength: Solution for injection, concentrate for solution for infusion, 2,5 mg/ml, 5 mg/ml, 7,5 mg/ml, 0,625 mg/ml, 1,25 mg/ml

More information

See Through The Masquerade To Avoid Paying Twice

See Through The Masquerade To Avoid Paying Twice See Through The Masquerade To Avoid Paying Twice Vladimir Bokarius, MD, PhD, QME CWCDAA Conference, October, 2018 Las Vegas, NV Agenda Mental Health Mental or Medical? Mental Health Disorders Due to General

More information

Karl McManus Foundation Representing the Australian Lyme Disease Community Symptoms Monitoring Chart

Karl McManus Foundation Representing the Australian Lyme Disease Community Symptoms Monitoring Chart Name Diagnosis Date Pathogens Present Date GENERAL Fever Chills Night sweats Fatigue Poor Stamina Weight Loss/Gain Gernalised Pain Migratory Pain Shooting Pain Daytime Napping Menstrual Irregularity Milk

More information

Sick Call Screener Course

Sick Call Screener Course Sick Call Screener Course SOAP Note (1.3) 1.3-2-1 Enabling Objective 1.5 Document a patient encounter 1.3-2-2 SOAP Note Standard for documentation Designed to allow easy reference for follow-up care. (U.S.

More information

Package leaflet: Information for the user Zirtek Allergy Relief for Children 1 mg/ml Oral Solution Cetirizine dihydrochloride

Package leaflet: Information for the user Zirtek Allergy Relief for Children 1 mg/ml Oral Solution Cetirizine dihydrochloride Package leaflet: Information for the user Zirtek Allergy Relief for Children 1 mg/ml Oral Solution Cetirizine dihydrochloride Read all of this leaflet carefully before you start taking this medicine because

More information

Package leaflet: Information for the user Zirtek Allergy Relief 10 mg Film Coated Tablets Cetirizine dihydrochloride

Package leaflet: Information for the user Zirtek Allergy Relief 10 mg Film Coated Tablets Cetirizine dihydrochloride Package leaflet: Information for the user Zirtek Allergy Relief 10 mg Film Coated Tablets Cetirizine dihydrochloride Read all of this leaflet carefully before you start taking this medicine because it

More information

MEDICATION GUIDE Savella (Sa-vel-la) (milnacipran HCl) Tablets

MEDICATION GUIDE Savella (Sa-vel-la) (milnacipran HCl) Tablets FDA-Approved Medication Guide MEDICATION GUIDE Savella (Sa-vel-la) (milnacipran HCl) Tablets Savella is not used to treat depression, but it acts like medicines that are used to treat depression (antidepressants)

More information

PERSONAL MEDICAL AND FAMILY HISTORY Please check applicable boxes.

PERSONAL MEDICAL AND FAMILY HISTORY Please check applicable boxes. Name: DOB: PERSONAL MEDICAL AND FAMILY HISTORY Please check applicable boxes. TOBACCO USE: Quit Date Cigarettes Packs/Day Number of years smoked Pipe/Cigar Smokeless Tobacco Electronic or E-cigarette Secondhand

More information

One Year Post Exclusivity Adverse Event Review CONCERTA

One Year Post Exclusivity Adverse Event Review CONCERTA 1 One Year Post Exclusivity Adverse Event Review CONCERTA Pediatric Advisory Committee Meeting June 30, 2005 Susan K. McCune, M.D. Medical Officer Division of Pediatric Drug Development Center for Drug

More information

Treatment of Alzheimer s disease

Treatment of Alzheimer s disease NORTH AND EAST DEVON HEALTHCARE COMMUNITY SHARED CARE PRESCRIBING GUIDELINE http://www.devonpct.nhs.uk/treatments/ne_devon_shared_care_guidelines.aspx#a Treatment of Alzheimer s disease Acetylcholinesterase

More information

Anne M. Calkins, 1 Joseph Shurman, 2 Mark Jaros, 3 Richard Kim, 4 Gwendoline Shang 4. New York Spine and Wellness Center, North Syracuse, NY; 2

Anne M. Calkins, 1 Joseph Shurman, 2 Mark Jaros, 3 Richard Kim, 4 Gwendoline Shang 4. New York Spine and Wellness Center, North Syracuse, NY; 2 Peripheral Edema and Weight Gain in Adult Patients With Painful Diabetic Peripheral Neuropathy Receiving Gabapentin Enacarbil or Pregabalin Enrolled in a Randomized, Phase 2 Trial Anne M. Calkins, 1 Joseph

More information

PATIENT GROUP DIRECTION (PGD) For the Supply of Varenicline (Champix )

PATIENT GROUP DIRECTION (PGD) For the Supply of Varenicline (Champix ) PATIENT GROUP DIRECTION (PGD) For the Supply of Varenicline (Champix ) Version: 1.3 Name of Originator/Author: Nicola Crocker Approved by: Trudi Grant, Director of Public Health Somerset County Council

More information

FOI CAERS Reports Allegedly Related to Multiple Energy Drinks

FOI CAERS Reports Allegedly Related to Multiple Energy Drinks FOI 14-17 Reports Allegedly Related to Multiple Energy Drinks Search Terms: Products Listed FDA s Center for Food Safety and Applied Nutrition s (CFSAN s) Adverse Event Reporting System () is a post-market

More information

PROFESSIONAL INFORMATION

PROFESSIONAL INFORMATION SCHEDULING STATUS: S2 PROPRIETARY NAME AND DOSAGE FORM: DEMAZIN NS REPETABS COMPOSITION: Active Ingredients: Each DEMAZIN NS REPETAB contains 5 mg loratadine (micronised) in the tablet coating and 120

More information